Soligenix (NASDAQ:SNGX – Get Free Report) posted its quarterly earnings data on Friday. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.05, Zacks reports.
Soligenix Price Performance
Shares of SNGX traded up $0.00 during trading hours on Friday, hitting $0.34. The company’s stock had a trading volume of 115,354 shares, compared to its average volume of 2,349,440. The business has a 50 day simple moving average of $0.36 and a two-hundred day simple moving average of $0.67. Soligenix has a 52-week low of $0.28 and a 52-week high of $1.70. The company has a market cap of $4.97 million, a price-to-earnings ratio of -0.34 and a beta of 2.04.
Analysts Set New Price Targets
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Soligenix in a research note on Thursday, October 15th. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat, Soligenix currently has a consensus rating of “Sell”.
View Our Latest Research Report on Soligenix
About Soligenix
Soligenix, Inc is a U.S.-based biopharmaceutical company focused on developing treatments for rare diseases and serious medical conditions with limited therapeutic options. The company’s programs are primarily aimed at immunology, inflammation, infectious diseases and oncology, with an emphasis on advancing candidates through clinical development and regulatory approval.
Soligenix’s pipeline has included SGX301, a synthetic hypericin-based photodynamic therapy being developed for cutaneous T-cell lymphoma; SGX942, an innate defense regulator investigated for inflammatory conditions such as oral mucositis; and SGX945, a related candidate studied for Behçet’s disease.
Featured Stories
- Five stocks we like better than Soligenix
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.
